Core Insights - United Therapeutics Corp reported fourth-quarter earnings of $7.70 per share, exceeding the analyst consensus estimate of $7.09 per share [1] - The company's quarterly sales were $790.200 million, which fell short of the analyst consensus estimate of $813.077 million [1] Financial Performance - The earnings per share of $7.70 represents a positive surprise compared to expectations [1] - Quarterly sales of $790.200 million indicate a revenue miss relative to analyst forecasts [1] Management Commentary - Martine Rothblatt, CEO, highlighted the company's record total revenue for the fourth consecutive year and expressed gratitude to employees for their commitment to innovation [2] - The CEO mentioned upcoming clinical programs, ADVANCE OUTCOMES and TETON-1, which are expected to provide pivotal data for new treatment options, potentially leading to transformational growth for the company [2] Market Reaction - Following the earnings announcement, United Therapeutics shares experienced a decline of 5.6%, trading at $505.28 [2] Analyst Reactions - Analysts adjusted their price targets for United Therapeutics in response to the earnings announcement [3]